Rick discusses the rigorous stages of drug approval, emphasizing the extensive preclinical and clinical trials required by the FDA. He highlights the lengthy phase two studies for MDMA, which have been ongoing for nearly a decade, and notes the wealth of data available on substances like marijuana and LSD due to their widespread use. This wealth of information offers unique insights into the safety and efficacy of these drugs compared to traditional pharmaceuticals.
